Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...

These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

In August, the FDA also approved updated mRNA COVID-19 vaccines, which also have a "monovalent (single) component" ...

KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results ...

On August 22, Moderna announced that FDA approved its supplemental Biologics License Application ... we saw more than 600,000 hospitalizations due to COVID in the U.S.” On the same day, Pfizer and ...

Pfizer ($PFE) became a household name during the pandemic, and its stock rose along with its fame. However, three years later ...

Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study ... iv Despite its severity, there are no FDA-approved treatments for cachexia. iii About Ponsegromab Ponsegromab ...